

JC01 Rec'd PCT/F 02 SEP 2005
PTO/SB/21 (08-00) *PCT*
AK3

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

 TRANSMITTAL FORM <small>PATENT & TRADEMARK OFFICE</small> <small>be used for all correspondence after initial filing</small>		Application Number	10/536,927
		Filing Date	May 31, 2005
		First Named Inventor	David Frederick HORROBIN
		Group Art Unit	Not yet assigned
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission		Attorney Docket Number	56170/316314

ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers <small>(for an Application)</small> <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <small>Change of Correspondence Address</small> <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group <small>(Appeal Notice, Brief, Reply Brief)</small> <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter	<input type="checkbox"/> Other Enclosure(s) <small>(please identify below):</small> 1. Form PTO/SB/08 (one sheet) 2. 7 publications 3. Return Receipt Postcard
Remarks			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Bruce D. Gray, Reg. No. 35,799
Signature	
Date	August 31, 2005

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 2233-1450 on this date:

Typed or printed name	<i>Gina Hamrick</i>		
Signature	Gina Hamrick	Date	August 31, 2005

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Docket No.: 56170/316314

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: David Frederick HORROBIN (deceased), et al.

Serial No.: 10/536,927 Group Art Unit: Not yet assigned

Filed: May 31, 2005 Examiner: Not yet Assigned

For: **TREATMENT OF HUNTINGTON'S DISEASE WITH EPA**

Commissioner for Patents
P.O. Box 1450
Alexandria VA, 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with Rules 56, 97 and 98 of the Rules of Practice in Patent Cases (37 C.F.R. §§ 1.56, 1.97, and 1.98), the publications listed on the modified Form PTO-1449 are enclosed with this submission for consideration by the Examiner.


Submission of the references provided in this Information Disclosure Statement is not intended to constitute an admission that any reference referred to herein is prior art for this invention unless specifically designated as such. Also, in accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that an exhaustive search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists.

In accordance with 37 C.F.R. §1.98(d), copies of the cited references are not enclosed as they were previously cited in prior application No. 09/835,453 (now allowed), to which the instant application relies upon for an earlier filing date under 35 U.S.C. 120.

U.S.S.N.: 10/440,802
Filed: May 19, 2003
For: Coatings for Metal Casting Parts
INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement is being filed before the issuance of a first office action on the merits of the application (37 C.F.R. 1.97(b)(3)); therefore, no fee is believed to be due. If a fee is due, the Commissioner is authorized to charge such fee and any additional fees that may be due or credit any overpayment to Deposit Account No. 11-0855.

Respectfully submitted,



Bruce D. Gray
Reg. No. 35,799

Date: August 31, 2005

KILPATRICK STOCKTON LLP
Suite 2800, 1100 Peachtree Street
Atlanta, Georgia 30309-4530
(404) 815-6218

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Application Number	
		April 16, 2003	
		First Named Inventor	
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	
SERIAL NO.	10/375,875	of	1

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		EP 0 614 977 A2	3/7/1994	The General Hospital Corporation		
		WO 99/15639	4/1/1999	McGill University		
		WO 00/44361	8/3/2000	Laxdale Limited		
		WO 01/24781 A2	4/12/2001	Nova-Neuron Inc.		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
		MARTHA A. NANCE, M.D. "Clinical Aspects of CAG Repeat Diseases," Brain Pathology 7:881-900 (1997)		
		NINA WILLUMSEN, ET AL. "On the effect of 2-deuterium-and 2-methyl-eicosapentaenoic acid derivatives on triglycerides, peroxisomal β -oxidation and platelet aggregation in rats," Biochimica et Biophysica Acta 1369 (1998) 193-203		
		MARK W. BERCHER, ET AL. "Intranuclear Neuronal Inclusion in Huntington's Disease and Dentatorubral and Pallidoluysian Atrophy: Correlation Between the Density of Inclusions and IT15 CAG Triplet Repeat Length," Menrobioogy of Disease 4, 387-397 (1998) Article No. NB980168		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.